Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients

Purpose: To identify prognostic factors in 262 patients with supradiaphragmatic Hodgkin's disease (HD), clinical stages (CS) I and II, prospectively treated between 1981 and 1988 according to the Paris-Ouest-France (POF) 81/ 12 protocol by three 1-month cycles of doxorubicin, bleomycin, vinblastine, and decarbazine plus methylprednisone (ABVD-MP) followed by subtotal nodal irradiation (RT). Patients and Methods: The size of mediastinal tumor (MT) was measured in all patients: 66 did not have MT (NoMT); 105 Rad a small-size MT (SSMT), ie, dediastinal mass ratio (MMR) less than 0.33; 58 had a medium-size MT (MSMT), ie, MMR greater than or equal to 0.33 and less than 0.45; and 33 had a bulky MT (BuMT), ie, MMR greater than or equal to 0.45, All patients received three cycles (CS IA, one cycle only) of ABVD-MP; patients in partial remission (PR) or complete remission (CR) sifter chemotherapy (PR) received supradiaphragmatic RT (involved fields, 40 Gy; adjacent fields, 30 Gy) plus lumboaortic and splenic RT (30 Gy); patients not in CR or PR after CT received salvage CT. Results: Two hundred seventeen patients (82.8%) entered CR after CT and 258 (98.5%) after RT. Ten-year freedom-from-progression (FFP) and survival rateswere 88.6% and 89.4%, respectively. According to univariate analysis, MF size and post-CT status were the only factors to influence both FFP and survival. For patients with NoMT or SSMT, those with MSMT, and those with BuMT, FFP rates were 94.1%, 87.0%, and 63.0% (P < .001), respectively, while corresponding survival rates were 92.6%, 87.2%, and 78.2% (P < .05). FFP rates were significantly different between the patients who achieved CR and those who did not achieve CR after CT: 94.6% versus 65.3% (P < .001); corresponding survival rates were 89.9% and 73.7% (P < .01). Multivariate analysis confirmed that MT size and post-CT status were the only two prognostic factors for FFP; for survival, the same two characteristics, as well as age (< 40 v 2 greater than or equal to 40 years), significantly effected prognosis. We were thus able to identify three groups. The 33 patients (12.6%) with a BuMT had 10-year FFP and survival rates of 63.0% and 78.2%, respectively. Of 229 patients without BuMT, the 195 who attained CR after CT herd an optimal prognosis (FFP, 96.6%; survival, 93.6%), while those who failed to achieve CR after CT had an intermediate prognosis (FFP, 68.8%; survival, 77.6%). Conclusion: These results demonstrate the independent impact on HD prognosis of tumor burden and post-CT status. (C) 1996 by American Society of Clinical Oncology.